Table 1 Patients’ characteristics and results obtained with cetuximab
From: Cetuximab in small bowel adenocarcinoma: a new friend?
Total number | 4 |
Age (years) | |
Median (minimum–maximum) | 64.25 (57–61) |
Gender, number (%) | |
Male | 3 (75) |
Female | 1 (25) |
Primary site (%) | |
Duodenum | 2 (50) |
Jejunum | 2 (50) |
Grading, number (%) | |
Well differentiated | 0 (0) |
Moderately differentiated | 1 (25) |
Poorly differentiated | 2 (50) |
KRas status | |
Wild-type | 3 (75%) |
Mutant | 0 (0%) |
Not available | 1 (25%) |
Response to cetuximab | |
Progression | 0 (0%) |
Stable disease (second line) | 1 (25%) |
Partial response (first and second line) | 2 (50%) |
Complete response (first line) | 1 (25%) |
Skin rash | |
G0 | 1 (25%) |
G1 | 0 (0%) |
G2 | 3 (75%) |
